UTas ePrintsTechnology evaluation: MRA, ChugaiCDingauthorGJonesauthorChugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.320503 Clinical Pharmacology and Therapeutics2003Article

Permissions, Copyright and Authorship Statement
I grant the University of Tasmania permission to copy, store and communicate this work I declare that I either own the copyright in the work or I am submitting this work with permission of the copyright owner or under licence from the copyright owner. I declare that the metadata regarding authorship are true and correct and that it complies with the authorship requirements set down in the Joint NHMRC/AVCC Guidelines on Research and Practice.

Clicking on the deposit button indicates your agreement to these terms.